We assessed the impact of these compounds using colony-formation assays of five myeloid leukemia cell lines representing distinct subtypes: THP-1 (AML, MLL-AF9), MV4-11 (AML, FLT3-ITD), HL60 (AML, TP53-null), K562 (CML, BCR-ABL1), and KG1a (AML, mutant TP53), a LSC-like cell line resistant to conventional chemotherapeutic agents (e.g., doxorubicin and cytarabine) [34]. The gene discussed is TP53; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.